Get the Stockscreener App
4.70
0.00%
0.00
After Hours:
4.70
Cytek Biosciences Inc stock is traded at $4.70, with a volume of 478.23K.
It is up +0.00% in the last 24 hours and up +9.81% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
See More
Previous Close:
$4.70
Open:
$4.67
24h Volume:
478.23K
Relative Volume:
0.37
Market Cap:
$610.92M
Revenue:
$204.17M
Net Income/Loss:
$-74.00M
P/E Ratio:
-8.1385
EPS:
-0.5775
Net Cash Flow:
$-12.84M
1W Performance:
+0.43%
1M Performance:
+9.81%
6M Performance:
+6.58%
1Y Performance:
+18.09%
1-Day Range:
$4.62
$4.7285
1-Week Range:
$4.48
$4.805
52-Week Range:
$3.28
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.70 | 605.72M | 204.17M | -74.00M | -12.84M | -0.5775 |
ABT
Abbott Laboratories
|
108.33 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.17 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
303.13 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
47.80 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.90 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-09-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
View All
Cytek Biosciences Inc Stock (CTKB) Latest News
Cytek Biosciences Showcases Advanced Spectral Flow Cytometry Solutions At Escca and Iccs - marketscreener.com
Cytek Biosciences (CTKB) officer plans $146K share sale - Stock Titan
Cytek Biosciences stock holds near recent levels as investor conferences approach - AD HOC NEWS
Cytek Biosciences to Participate in Upcoming Investor Conferences - Yahoo Finance
Cytek Owes Beckman Coulter $56 Million at Patent Jury Trial (2) - Bloomberg Law News
Cytek Hit With $56M Verdict For Infringing Cell-Sorting Patent - Law360
Cytek Biosciences wins on three of four patent claims - Investing.com
Cytek Biosciences wins on three of four patent claims By Investing.com - Investing.com Nigeria
Cytek owes Beckman Coulter $56 mln in cell-analysis patent case, US jury says - Reuters
Cytek products remain available worldwide after jury awards $36M in royalties - Stock Titan
Cytek Biosciences CFO William D. McCombe Executes RSU Vesting and Tax Withholding Transactions - Kalkine Media
Cytek Biosciences Director Glenn P. Muir Converts 3,086 RSUs to Common Stock on August 18, 2026 - Kalkine Media
Cytek Biosciences (CTKB) CEO gets 120K shares, surrenders some for taxes - Stock Titan
Cytek Biosciences (NASDAQ: CTKB) director gains 3,086 no-cost shares - Stock Titan
Cytek Biosciences (CTKB) director now holds 28,499 shares - Stock Titan
Cytek Biosciences (CTKB) CTO gets 33,270 shares, surrenders some for taxes - Stock Titan
Cytek (CTKB) Quarterly Figures: EPS Prints Above Forecast in the Latest Session; Stock Move: Shares Finish 0.96% HigherEstimate Dispersion - vinanet.vn
Cytek Biosciences CEO Wenbin Jiang Completes RSU Vesting and Tax Withholding Share Surrender - Kalkine Media
Cytek Biosciences Balances Growth With Profit Pressures - TipRanks
Cytek (CTKB) Q2 2026 Earnings Call Transcript - AOL.com
Cytek Biosciences (CTKB) awards 241,416 RSUs and 127,118 options to top lawyer - Stock Titan
Cytek Biosciences: Recurring Revenue Reaches 35% Of Sales As Installed Base Approaches 4,000 Instruments - Pulse 2.0
Cytek Biosciences launches Aurora Evo system to drive high-throughput research and small particle detection - Traders Union
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Cytek Biosciences (NASDAQ:CTKB) Trading 8.5% HigherShould You Buy? - MarketBeat
Cytek Biosciences, Inc. (8EQ.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cytek Biosciences (CTKB) and Sight Sciences (SGHT) - The Globe and Mail
Cytek Biosciences, Inc. (CTKB) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore
Cytek Biosciences (CTKB) holders report over 7% stakes in Schedule 13G/A - Stock Titan
Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Morgan Stanley Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Cuts Target Price to $5 - Moomoo
TD Cowen Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $5 - Moomoo
Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ... - Yahoo! Finance Canada
Cytek Biosciences Q2 2026 Earnings Report: Financial Highlights, Revenue Growth, and Investor Insights - Minichart
CTKB Looks 28.3% Undervalued on GF Value™ Despite Unprofitable S - GuruFocus
Cytek Biosciences (NASDAQ:CTKB) Posts Earnings Results, Hits Estimates - MarketBeat
Cytek Biosciences Q2 Earnings Call Highlights - MarketBeat
Cytek Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cytek Biosciences earnings missed, revenue fell short of estimates - Investing.com
Earnings call transcript: Cytek Biosciences posts q2 2026 revenue growth, shares fall - Investing.com Nigeria
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Cytek Biosciences (CTKB) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss - Quiver Quantitative
Cytek Biosciences, Inc. 2Q 2026: Revenue $48.14M, EPS ($0.09) — 10-Q Summary - TradingView
Cytek Biosciences Q2 revenue slightly misses estimates - TradingView
Cytek Biosciences Q2 2026: Revenue $48.1M, Gross Profit $28.3M, Net Loss $12.2M - TradingView
Cytek Biosciences, Inc. Raising Revenue Guidance for the Full Year 2026 - marketscreener.com
Cytek Biosciences Reports Second Quarter 2026 Financial Results - The Manila Times
Cytek Biosciences Q2 GAAP net loss widens to $12.2 million; revenue rises 6% year over year to $48.1 million - Bitget
Cytek Biosciences (CTKB) Dips 2.3% to $4.18 as Support at $3.97 Comes into FocusAnchored VWAP - vinanet.vn
Cytek Biosciences incentivizes larger reagent purchases with free summer gifts - Traders Union
Boston Partners (CTKB) discloses 7.64M-share beneficial stake in Cytek Biosciences - stocktitan.net
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):